tiprankstipranks
Advertisement
Advertisement
Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions
PremiumCompany AnnouncementsEdgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions
1M ago
Edgewise Therapeutics price target raised to $45 from $30 at Evercore ISI
Premium
The Fly
Edgewise Therapeutics price target raised to $45 from $30 at Evercore ISI
2M ago
Edgewise Therapeutics reports Q4 EPS (47c), consensus (44c)
Premium
The Fly
Edgewise Therapeutics reports Q4 EPS (47c), consensus (44c)
2M ago
Edgewise Therapeutics rises 20.3%
PremiumThe FlyEdgewise Therapeutics rises 20.3%
4M ago
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating
Premium
Ratings
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating
4M ago
H.C. Wainwright says Edgewise data reinforces EDG-7500 potential differentiation
Premium
The Fly
H.C. Wainwright says Edgewise data reinforces EDG-7500 potential differentiation
4M ago
Edgewise Therapeutics reports ‘positive’ updates from Phase 2 EDG-7500 trial
PremiumThe FlyEdgewise Therapeutics reports ‘positive’ updates from Phase 2 EDG-7500 trial
4M ago
Edgewise Therapeutics falls -10.7%
Premium
The Fly
Edgewise Therapeutics falls -10.7%
4M ago
Edgewise Therapeutics falls -9.9%
Premium
The Fly
Edgewise Therapeutics falls -9.9%
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100